We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Brentuximab Vedotin + Re-induction Chemotherapy for AML

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01830777
Recruitment Status : Recruiting
First Posted : April 12, 2013
Last Update Posted : December 21, 2017
Information provided by (Responsible Party):
Amir Fathi, Massachusetts General Hospital

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Recruiting
  Estimated Primary Completion Date : December 2018
  Estimated Study Completion Date : December 2019